Maxim Group Maintains Mainz Biomed(MYNZ.US) With Buy Rating, Maintains Target Price $14
Strategic Collaboration and Innovative Biomarkers Drive Buy Rating for Mainz Biomed
Mainz Biomed Analyst Ratings
Maxim Group Initiates Coverage On Mainz Biomed With Buy Rating, Announces Price Target of $14
Maxim Group Initiates Mainz Biomed(MYNZ.US) With Buy Rating, Announces Target Price $14
Mainz Biomed Analyst Ratings
H.C. Wainwright Downgrades Mainz Biomed(MYNZ.US) to Hold Rating
Mainz Biomed Analyst Ratings
Analysts' Top Healthcare Picks: Mainz Biomed B.V. (MYNZ), Century Therapeutics (IPSC)
Mainz Biomed Analyst Ratings
HC Wainwright & Co. Maintains Buy on Mainz Biomed, Lowers Price Target to $3
Analysts Are Bullish on Top Healthcare Stocks: Iterum Therapeutics (ITRM), Mainz Biomed B.V. (MYNZ)
Mainz Biomed B.V.: Buy Rating With High CRC Detection Success and AI Integration
Analysts Are Bullish on Top Healthcare Stocks: Mainz Biomed B.V. (MYNZ), Agile Therapeutics (AGRX)
Mainz Biomed Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Mainz Biomed B.V. (MYNZ), Xencor (XNCR) and Biotricity (BTCY)
HC Wainwright & Co. Maintains Buy on Mainz Biomed, Lowers Price Target to $5
Mainz Biomed Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Mainz Biomed, Maintains $9 Price Target
Mainz Biomed Analyst Ratings